Leiomyosarcoma — Trials

Leiomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

135 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 38
Recruiting: 25
Ph III recruiting: 2
Growth YoY: —
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–12 of 12 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02923778	Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery	active not recruiting	Phase 2	40	National Cancer Institute (NCI)NIH	2	Sep 25, 2026	clinicaltrials
NCT06308419	A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions	active not recruiting	Phase 1	18	M.D. Anderson Cancer CenterOTHER	1